A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer

BACKGROUND: The aim of our retrospective study was to evaluate the 5-year survival and time to castration resistant prostate cancer in patients with hormone sensitive prostate cancer treated with the gonadotropin releasing hormone antagonist, degarelix. Another aim was to evaluate the effects of cha...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Basic Clin Androl
Päätekijät: Asakawa, Jumpei, Iguchi, Taro, Tamada, Satoshi, Yasuda, Sayaka, Ninomiya, Noriko, Kato, Minoru, Yamasaki, Takeshi, Ohmachi, Tetusji, Nakatani, Tatsuya
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
https://ncbi.nlm.nih.gov/pubmed/30026950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12610-018-0074-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia